Brokerages Set Cigna Group (NYSE:CI) PT at $339.50

Cigna Group (NYSE:CI) has been assigned a consensus recommendation of “Moderate Buy” from the twenty-one analysts that are currently covering the stock, Marketbeat Ratings reports. Six investment analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $339.50.

Several research firms have weighed in on CI. Morgan Stanley boosted their price target on Cigna Group from $355.00 to $361.00 and gave the company an “overweight” rating in a research note on Wednesday, May 20th. Truist Financial boosted their price target on Cigna Group from $320.00 to $350.00 and gave the company a “buy” rating in a research note on Tuesday, February 17th. TD Cowen boosted their price target on Cigna Group from $333.00 to $338.00 and gave the company a “buy” rating in a research note on Monday, February 9th. Wall Street Zen upgraded Cigna Group from a “hold” rating to a “buy” rating in a research note on Saturday, February 7th. Finally, Leerink Partners boosted their price target on Cigna Group from $270.00 to $297.00 and gave the company a “market perform” rating in a research note on Friday, February 6th.

Cigna Group Trading Down 2.5%

Shares of NYSE:CI opened at $277.08 on Thursday. The business’s 50-day moving average is $278.32 and its 200 day moving average is $276.88. Cigna Group has a 1 year low of $239.51 and a 1 year high of $338.89. The firm has a market capitalization of $73.30 billion, a P/E ratio of 11.75, a P/E/G ratio of 1.00 and a beta of 0.30. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.73 and a quick ratio of 0.73.

Cigna Group (NYSE:CI) last posted its quarterly earnings results on Thursday, April 30th. The health services provider reported $7.79 earnings per share for the quarter, beating the consensus estimate of $7.60 by $0.19. The business had revenue of $68.52 billion for the quarter, compared to the consensus estimate of $66.29 billion. Cigna Group had a return on equity of 19.75% and a net margin of 2.26%.The company’s quarterly revenue was up 4.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $6.74 EPS. Cigna Group has set its FY 2026 guidance at 30.350- EPS. On average, research analysts predict that Cigna Group will post 30.39 earnings per share for the current fiscal year.

Cigna Group Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, June 18th. Stockholders of record on Thursday, June 4th will be paid a $1.56 dividend. The ex-dividend date is Thursday, June 4th. This represents a $6.24 dividend on an annualized basis and a dividend yield of 2.3%. Cigna Group’s dividend payout ratio is presently 26.45%.

Insider Transactions at Cigna Group

In other news, CEO David Cordani sold 201,878 shares of the company’s stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $292.82, for a total value of $59,113,915.96. Following the sale, the chief executive officer owned 34,337 shares in the company, valued at $10,054,560.34. This represents a 85.46% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Nicole S. Jones sold 2,307 shares of the company’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $288.91, for a total value of $666,515.37. Following the completion of the sale, the insider owned 32,647 shares in the company, valued at $9,432,044.77. The trade was a 6.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 205,904 shares of company stock worth $60,277,068 over the last quarter. 0.60% of the stock is currently owned by insiders.

Institutional Trading of Cigna Group

A number of hedge funds have recently modified their holdings of the stock. Asset Dedication LLC boosted its stake in shares of Cigna Group by 91.3% in the first quarter. Asset Dedication LLC now owns 2,129 shares of the health services provider’s stock worth $568,000 after buying an additional 1,016 shares during the last quarter. Maripau Wealth Management LLC boosted its position in Cigna Group by 4.0% during the first quarter. Maripau Wealth Management LLC now owns 1,074 shares of the health services provider’s stock worth $287,000 after purchasing an additional 41 shares in the last quarter. Allen Capital Group LLC boosted its position in Cigna Group by 6.4% during the first quarter. Allen Capital Group LLC now owns 794 shares of the health services provider’s stock worth $212,000 after purchasing an additional 48 shares in the last quarter. Groupe la Francaise boosted its position in Cigna Group by 6.3% during the first quarter. Groupe la Francaise now owns 17,613 shares of the health services provider’s stock worth $4,698,000 after purchasing an additional 1,041 shares in the last quarter. Finally, Western Wealth Management LLC purchased a new position in Cigna Group during the first quarter worth approximately $61,000. Hedge funds and other institutional investors own 86.99% of the company’s stock.

Cigna Group Company Profile

Cigna Group (NYSE: CI) is a global health services company that offers a broad portfolio of healthcare products and insurance solutions for individuals, employers, and governments. Its core businesses include medical and behavioral health plans, dental and vision coverage, pharmacy benefit management, and supplemental health products. Cigna serves a mix of commercial, Medicare, and Medicaid customers and provides workplace benefits such as group health plans and disability and life benefits for employers.

In addition to traditional insurance products, Cigna operates health services and care-delivery platforms designed to manage costs and improve outcomes.